Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
InMed Pharmaceuticals announces milestones for 2023 » 07:36
01/10/23
01/10
07:36
01/10/23
07:36
INM

InMed Pharmaceuticals

$1.69 /

+0.09 (+5.63%)

InMed Pharmaceuticals…

InMed Pharmaceuticals outlines key accomplishments from 2022 and provides business update and catalysts for 2023. Business update and upcoming milestones: INM-755 - Phase 2 clinical trial in the treatment of Epidermolysis Bullosa. To date, the Phase 2 clinical trial has enrolled 16 patients of its targeted 20 patients. Several additional prospective patients have been identified for screening at the clinical sites; therefore, the Company decided to extend the enrollment period to the end of March 2023. INM-088 - Advancing towards human trials: The Company continues to conduct the required preclinical work, including toxicology studies, and has planned several GLP studies in 2023 in advance of human clinical trials. On track to begin this clinical trial in 2024. INM-900 - Developing a new approach in neurodegenerative disease: InMed's ipeline was expanded this year with the addition of our neurodegenerative disease program. With recent promising preclinical data, InMed plans to expedite its INM-900 program for the potential treatment of neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease. Novel cannabinoid analogs - protecting the R&D investment: InMed continues to develop a valuable library of novel, proprietary cannabinoid analogs. These analogs are being selectively screened and developed for targeting specific disease outcomes, safety profiles, and/or pharmacological properties such as improved delivery. In addition, these novel cannabinoid analogs are patentable, increasing their commercial attractiveness for internal development or as licensing candidates to other drug development companies.

ShowHide Related Items >><<
INM InMed Pharmaceuticals
$1.69 /

+0.09 (+5.63%)

INM InMed Pharmaceuticals
$1.69 /

+0.09 (+5.63%)

01/09/23 Cowen
InMed Pharmaceuticals price target lowered to $45 from $53 at Cowen
05/16/22 Roth MKM
InMed Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
INM InMed Pharmaceuticals
$1.69 /

+0.09 (+5.63%)

INM InMed Pharmaceuticals
$1.69 /

+0.09 (+5.63%)

Recommendations
InMed Pharmaceuticals price target lowered to $45 from $53 at Cowen » 07:30
01/09/23
01/09
07:30
01/09/23
07:30
INM

InMed Pharmaceuticals

$1.63 /

-0.28 (-14.66%)

Cowen analyst Ritu Baral…

Cowen analyst Ritu Baral lowered the firm's price target on InMed Pharmaceuticals to $45 from $53 and keeps an Outperform rating on the shares. The analyst updated his model to reflect guidance and adjusted his target and forward estimates for growth and WW revenues while also noting the ASPEN study remains on track while brenso Ph2 PK/PD was clean.

ShowHide Related Items >><<
INM InMed Pharmaceuticals
$1.63 /

-0.28 (-14.66%)

INM InMed Pharmaceuticals
$1.63 /

-0.28 (-14.66%)

05/16/22 Roth MKM
InMed Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
INM InMed Pharmaceuticals
$1.63 /

-0.28 (-14.66%)

INM InMed Pharmaceuticals
$1.63 /

-0.28 (-14.66%)

Over a month ago
On The Fly
Sell these stocks now, proven algorithm says » 14:36
12/16/22
12/16
14:36
12/16/22
14:36
INM

InMed Pharmaceuticals

$1.81 /

-0.14 (-7.18%)

, MRTX

Mirati Therapeutics

$43.83 /

+1.33 (+3.13%)

, SE

Sea Limited

$54.57 /

-6.52 (-10.67%)

, TOST

Toast

$18.77 /

+0.015 (+0.08%)

, SHOP

Shopify

$35.85 /

-0.55 (-1.51%)

, EQX

Equinox Gold

$3.51 /

+0.03 (+0.86%)

, CFLT

Confluent

$22.87 /

-0.09 (-0.39%)

, XMTR

Xometry

$32.67 /

-1.62 (-4.72%)

, RADI

Radius Global Infrastructure

$12.09 /

-0.17 (-1.39%)

, PL

Planet Labs

$5.32 /

+0.37 (+7.47%)

, PSFE

Paysafe

$11.69 /

-0.26 (-2.18%)

, FREY

Freyr Battery

$10.36 /

-0.535 (-4.91%)

, VERV

Verve Therapeutics

$18.96 /

-0.6 (-3.07%)

, CCL

Carnival

$8.38 /

-0.275 (-3.18%)

, EVA

Enviva

$54.63 /

-1.645 (-2.92%)

, RXRX

Recursion Pharmaceuticals

$8.13 /

-0.33 (-3.90%)

, MAXR

Maxar Technologies

$51.49 /

+28.44 (+123.38%)

Here are this week's…

ShowHide Related Items >><<
XMTR Xometry
$32.67 /

-1.62 (-4.72%)

VERV Verve Therapeutics
$18.96 /

-0.6 (-3.07%)

TOST Toast
$18.77 /

+0.015 (+0.08%)

SHOP Shopify
$35.85 /

-0.55 (-1.51%)

SE Sea Limited
$54.57 /

-6.52 (-10.67%)

RXRX Recursion Pharmaceuticals
$8.13 /

-0.33 (-3.90%)

RADI Radius Global Infrastructure
$12.09 /

-0.17 (-1.39%)

PSFE Paysafe
$11.69 /

-0.26 (-2.18%)

PL Planet Labs
$5.32 /

+0.37 (+7.47%)

MRTX Mirati Therapeutics
$43.83 /

+1.33 (+3.13%)

MAXR Maxar Technologies
$51.49 /

+28.44 (+123.38%)

INM InMed Pharmaceuticals
$1.81 /

-0.14 (-7.18%)

FREY Freyr Battery
$10.36 /

-0.535 (-4.91%)

EVA Enviva
$54.63 /

-1.645 (-2.92%)

EQX Equinox Gold
$3.51 /

+0.03 (+0.86%)

CFLT Confluent
$22.87 /

-0.09 (-0.39%)

CCL Carnival
$8.38 /

-0.275 (-3.18%)

INM InMed Pharmaceuticals
$1.81 /

-0.14 (-7.18%)

05/16/22 Roth MKM
InMed Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
MRTX Mirati Therapeutics
$43.83 /

+1.33 (+3.13%)

12/14/22 Needham
Mirati Therapeutics initiated with a Hold at Needham
12/14/22 Barclays
Mirati Therapeutics price target lowered to $90 from $169 at Barclays
12/13/22 Piper Sandler
Mirati Therapeutics price target lowered to $68 from $87 at Piper Sandler
12/13/22 Piper Sandler
Mirati Therapeutics price target raised to $87 from $84 at Piper Sandler
SE Sea Limited
$54.57 /

-6.52 (-10.67%)

11/21/22 Cowen
Sea Limited downgraded on lack of visibility at Cowen
11/21/22 Cowen
Sea Limited downgraded to Market Perform from Outperform at Cowen
11/17/22 Morgan Stanley
Sea Limited price target lowered to $95 from $116 at Morgan Stanley
11/16/22 Cowen
Sea Limited price target lowered to $72 from $78 at Cowen
TOST Toast
$18.77 /

+0.015 (+0.08%)

12/16/22 Wells Fargo
Wells Fargo sees significant opportunity ahead for Toast
12/12/22 Mizuho
Fiserv price target lowered to $135 from $145 at Mizuho
11/29/22 Wolfe Research
Toast initiated with a Peer Perform at Wolfe Research
11/11/22 Needham
Toast price target raised to $32 from $27 at Needham
SHOP Shopify
$35.85 /

-0.55 (-1.51%)

12/09/22 SMBC Nikko
Shopify price target raised to $45 from $40 at SMBC Nikko
12/08/22 Capital One
Shopify initiated with an Equalweight at Capital One
12/08/22 UBS
Shopify initiated with a Sell at UBS
12/08/22 Mizuho
Shopify price target raised to $40 from $33 at Mizuho
EQX Equinox Gold
$3.51 /

+0.03 (+0.86%)

12/07/22 National Bank
Equinox Gold price target raised to C$5.50 from C$5 at National Bank
12/07/22 BMO Capital
Equinox Gold price target raised to C$6.50 from C$6 at BMO Capital
11/07/22 BMO Capital
Equinox Gold price target lowered to C$6 from C$7.50 at BMO Capital
11/04/22 National Bank
Equinox Gold price target lowered to C$4 from C$5 at National Bank
CFLT Confluent
$22.87 /

-0.09 (-0.39%)

11/03/22 DA Davidson
Confluent price target lowered to $33 from $44 at DA Davidson
11/03/22 Credit Suisse
Confluent price target lowered to $55 from $65 at Credit Suisse
11/03/22 Barclays
Confluent price target lowered to $27 from $30 at Barclays
11/01/22 Citi
Confluent price target lowered to $30 from $32 at Citi
XMTR Xometry
$32.67 /

-1.62 (-4.72%)

12/14/22 Lake Street
Xometry initiated with a Sell at Lake Street
12/13/22 Citi
Xometry initiated with a Buy at Citi
11/11/22 UBS
Xometry price target lowered to $45 from $55 at UBS
08/24/22 JPMorgan
JPMorgan cuts Xometry target but still sees 46% upside potential
RADI Radius Global Infrastructure
$12.09 /

-0.17 (-1.39%)

12/16/22 RBC Capital
Radius Global Infrastructure initiated with a Sector Perform at RBC Capital
12/14/22 Exane BNP Paribas
Radius Global Infrastructure initiated with an Outperform at Exane BNP Paribas
10/04/22 Raymond James
Radius Global Infrastructure price target lowered to $17 from $21 at Raymond James
05/10/22 Raymond James
Radius Global Infrastructure price target raised to $22 from $18 at Raymond James
PL Planet Labs
$5.32 /

+0.37 (+7.47%)

11/08/22 Deutsche Bank
Planet Labs initiated with a Buy at Deutsche Bank
09/13/22 Needham
Planet Labs price target raised to $9 from $8 at Needham
06/15/22 Craig-Hallum
Planet Labs price target lowered to $10 from $15 at Craig-Hallum
06/15/22 Needham
Planet Labs price target lowered to $8.00 from $10.50 at Needham
PSFE Paysafe
$11.69 /

-0.26 (-2.18%)

08/31/22 Susquehanna
Susquehanna downgrades Paysafe after CFO change, prefers to 'wait and see'
08/31/22 Susquehanna
Paysafe downgraded to Neutral from Positive at Susquehanna
08/11/22 Credit Suisse
Paysafe downgraded to Underperform from Neutral at Credit Suisse
08/10/22 RBC Capital
Paysafe downgraded to Sector Perform from Outperform at RBC Capital
FREY Freyr Battery
$10.36 /

-0.535 (-4.91%)

10/31/22 Cowen
Cowen starts Freyr Battery at Outperform, sees 'less technology risk'
10/31/22 Cowen
Freyr Battery initiated with an Outperform at Cowen
09/21/22 Morgan Stanley
Freyr Battery price target raised to $26, named a 'Top Pick' at Morgan Stanley
09/01/22 BTIG
Freyr Battery price target raised to $25 from $20 at BTIG
VERV Verve Therapeutics
$18.96 /

-0.6 (-3.07%)

12/15/22 Goldman Sachs
Verve Therapeutics initiated with a Sell at Goldman Sachs
12/05/22 Stifel
Verve FDA request 'provides fodder for both bulls and bears,' says Stifel
12/02/22 Guggenheim
Beam hold being lifted 'encouraging' for Verve Therapeutics, says Guggenheim
10/06/22 Credit Suisse
Verve Therapeutics initiated with a Neutral at Credit Suisse
CCL Carnival
$8.38 /

-0.275 (-3.18%)

12/15/22 Barclays
Carnival price target raised to $12 from $10 at Barclays
12/14/22 Stifel
Carnival price target raised to $18 at Stifel, would buy ahead of Q4 report
12/12/22 Credit Suisse
Credit Suisse keeps Outperform on Carnival, lowers price target to $19
12/06/22 JPMorgan
Carnival assumed with a Neutral at JPMorgan
EVA Enviva
$54.63 /

-1.645 (-2.92%)

11/29/22 RBC Capital
Enviva price target lowered to $63 from $76 at RBC Capital
10/20/22 JPMorgan
Enviva price target lowered to $60 from $66 at JPMorgan
10/18/22 Raymond James
Enviva upgraded to Strong Buy from Outperform at Raymond James
10/14/22 Citi
Citi upgrades Enviva to Buy, says short report selloff overdone
RXRX Recursion Pharmaceuticals
$8.13 /

-0.33 (-3.90%)

09/15/22 KeyBanc
Recursion Pharmaceuticals initiated with an Overweight at KeyBanc
04/18/22 BofA
Recursion Pharmaceuticals downgraded to Neutral from Buy at BofA
03/04/22 SVB Securities
Recursion Pharmaceuticals downgraded to Market Perform from Outperform at SVB Leerink
MAXR Maxar Technologies
$51.49 /

+28.44 (+123.38%)

12/16/22 Wells Fargo
Maxar Technologies downgraded to Equal Weight from Overweight at Wells Fargo
12/16/22 Canaccord
Maxar Technologies downgraded to Hold from Buy at Canaccord
12/16/22 Truist
Maxar Technologies downgraded to Hold from Buy at Truist
11/23/22 Truist
Maxar Technologies price target lowered to $37 from $44 at Truist
XMTR Xometry
$32.67 /

-1.62 (-4.72%)

VERV Verve Therapeutics
$18.96 /

-0.6 (-3.07%)

TOST Toast
$18.77 /

+0.015 (+0.08%)

SHOP Shopify
$35.85 /

-0.55 (-1.51%)

SE Sea Limited
$54.57 /

-6.52 (-10.67%)

RXRX Recursion Pharmaceuticals
$8.13 /

-0.33 (-3.90%)

RADI Radius Global Infrastructure
$12.09 /

-0.17 (-1.39%)

PSFE Paysafe
$11.69 /

-0.26 (-2.18%)

PL Planet Labs
$5.32 /

+0.37 (+7.47%)

MRTX Mirati Therapeutics
$43.83 /

+1.33 (+3.13%)

MAXR Maxar Technologies
$51.49 /

+28.44 (+123.38%)

INM InMed Pharmaceuticals
$1.81 /

-0.14 (-7.18%)

FREY Freyr Battery
$10.36 /

-0.535 (-4.91%)

EVA Enviva
$54.63 /

-1.645 (-2.92%)

EQX Equinox Gold
$3.51 /

+0.03 (+0.86%)

CFLT Confluent
$22.87 /

-0.09 (-0.39%)

CCL Carnival
$8.38 /

-0.275 (-3.18%)

  • 01
    Dec
  • 21
    Jul
  • 21
    Jul
  • 20
    Jan
  • 04
    Jan
SHOP Shopify
$35.85 /

-0.55 (-1.51%)

SE Sea Limited
$54.57 /

-6.52 (-10.67%)

RADI Radius Global Infrastructure
$12.09 /

-0.17 (-1.39%)

MRTX Mirati Therapeutics
$43.83 /

+1.33 (+3.13%)

EVA Enviva
$54.63 /

-1.645 (-2.92%)

CCL Carnival
$8.38 /

-0.275 (-3.18%)

XMTR Xometry
$32.67 /

-1.62 (-4.72%)

VERV Verve Therapeutics
$18.96 /

-0.6 (-3.07%)

TOST Toast
$18.77 /

+0.015 (+0.08%)

SHOP Shopify
$35.85 /

-0.55 (-1.51%)

SE Sea Limited
$54.57 /

-6.52 (-10.67%)

RXRX Recursion Pharmaceuticals
$8.13 /

-0.33 (-3.90%)

RADI Radius Global Infrastructure
$12.09 /

-0.17 (-1.39%)

PSFE Paysafe
$11.69 /

-0.26 (-2.18%)

PL Planet Labs
$5.32 /

+0.37 (+7.47%)

MRTX Mirati Therapeutics
$43.83 /

+1.33 (+3.13%)

MAXR Maxar Technologies
$51.49 /

+28.44 (+123.38%)

INM InMed Pharmaceuticals
$1.81 /

-0.14 (-7.18%)

FREY Freyr Battery
$10.36 /

-0.535 (-4.91%)

EVA Enviva
$54.63 /

-1.645 (-2.92%)

EQX Equinox Gold
$3.51 /

+0.03 (+0.86%)

CFLT Confluent
$22.87 /

-0.09 (-0.39%)

CCL Carnival
$8.38 /

-0.275 (-3.18%)

TOST Toast
$18.77 /

+0.015 (+0.08%)

SHOP Shopify
$35.85 /

-0.55 (-1.51%)

SE Sea Limited
$54.57 /

-6.52 (-10.67%)

PSFE Paysafe
$11.69 /

-0.26 (-2.18%)

PL Planet Labs
$5.32 /

+0.37 (+7.47%)

FREY Freyr Battery
$10.36 /

-0.535 (-4.91%)

EQX Equinox Gold
$3.51 /

+0.03 (+0.86%)

CFLT Confluent
$22.87 /

-0.09 (-0.39%)

CCL Carnival
$8.38 /

-0.275 (-3.18%)

Hot Stocks
InMed Pharmaceuticals engages Marcum LLP as auditor after KPMG resigns » 18:51
12/12/22
12/12
18:51
12/12/22
18:51
INM

InMed Pharmaceuticals

$1.92 /

-0.08 (-4.00%)

The Company…

The Company "announces that its auditor, KPMG has resigned effective as of December 8, 2022, and that the Audit Committee of the Board of Directors of the Company approved the engagement of Marcum LLP as its auditor, subject to Marcum's completion of their client acceptance procedures. Marcum will stand for appointment at the Company's Annual General Meeting, currently scheduled for Thursday, December 15, 2022. KPMG has confirmed that there are no reportable events (as such term is defined in National Instrument 51-102 - Continuous Disclosure Obligations."

ShowHide Related Items >><<
INM InMed Pharmaceuticals
$1.92 /

-0.08 (-4.00%)

INM InMed Pharmaceuticals
$1.92 /

-0.08 (-4.00%)

05/16/22 Roth MKM
InMed Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
INM InMed Pharmaceuticals
$1.92 /

-0.08 (-4.00%)

INM InMed Pharmaceuticals
$1.92 /

-0.08 (-4.00%)

Hot Stocks
InMed Pharmaceuticals names Jonathan Tegge as interim CFO » 18:49
12/12/22
12/12
18:49
12/12/22
18:49
INM

InMed Pharmaceuticals

$1.92 /

-0.08 (-4.00%)

InMed Pharmaceuticals…

InMed Pharmaceuticals "announces the Company has entered into a service contract with Brio Financial Group to provide senior financial leadership and bookkeeping services. Pursuant to the Contract, Mr. Jonathan Tegge, a member of Brio, will assume the role of Interim Chief Financial Officer for the Company effective December 12, 2022."

ShowHide Related Items >><<
INM InMed Pharmaceuticals
$1.92 /

-0.08 (-4.00%)

INM InMed Pharmaceuticals
$1.92 /

-0.08 (-4.00%)

05/16/22 Roth MKM
InMed Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
INM InMed Pharmaceuticals
$1.92 /

-0.08 (-4.00%)

INM InMed Pharmaceuticals
$1.92 /

-0.08 (-4.00%)

Hot Stocks
InMed Pharmaceuticals announces $6M private placement » 08:07
11/18/22
11/18
08:07
11/18/22
08:07
INM

InMed Pharmaceuticals

$3.81 /

-0.06 (-1.55%)

InMed Pharmaceuticals…

InMed Pharmaceuticals announced that it has entered into a securities purchase agreement with two healthcare-focused institutional investors for the issuance and sale of 1,818,185 of its common shares at a purchase price of $3.30 per share in a private placement priced at-the-market under Nasdaq rules. In addition, the Company has agreed to issue to the investors in the offering unregistered preferred investment options to purchase up to an aggregate of 3,272,733 common shares. The aggregate gross proceeds to the Company from the private placement is expected to be approximately $6 million. The offering is expected to close on or about November 21, 2022, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to continue pipeline development of its pharmaceutical drug candidates, advance manufacturing know-how of cannabinoids and cannabinoid analogs, support intellectual property development and other commercial activities, and for general working capital purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The unregistered investment options to be issued in the offering will be exercisable immediately upon issuance at an exercise price of $3.044 per share and will expire seven years from the date of issuance. In addition, the investors in the private placement agreed to cancel preferred investment options to purchase up to an aggregate of 1,382,490 common shares of the Company which were previously issued to the investors.

ShowHide Related Items >><<
INM InMed Pharmaceuticals
$3.81 /

-0.06 (-1.55%)

INM InMed Pharmaceuticals
$3.81 /

-0.06 (-1.55%)

05/16/22 Roth MKM
InMed Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
11/29/21 H.C. Wainwright
InMed Pharmaceuticals initiated with a Buy at H.C. Wainwright
INM InMed Pharmaceuticals
$3.81 /

-0.06 (-1.55%)

INM InMed Pharmaceuticals
$3.81 /

-0.06 (-1.55%)

Hot Stocks
InMed Pharmaceuticals annouces Li promoted to VP of accounting, controller » 07:31
11/17/22
11/17
07:31
11/17/22
07:31
INM

InMed Pharmaceuticals

$3.80 /

+1.05 (+38.18%)

InMed Pharmaceuticals…

InMed Pharmaceuticals announces that Sarah Li has been promoted to Vice President, VP, of Accounting and Controller at InMed. Brenda Edwards will be transitioning out of her position as interim Chief Financial Officer at the Company effective November 20, 2022. Edwards joined the Company in an interim contract role to assist the Company with financial reporting matters following the retirement of the Company's former Chief Financial Officer in March 2022. The Company is currently in discussions to finalize the engagement of interim financial leadership consulting services.

ShowHide Related Items >><<
INM InMed Pharmaceuticals
$3.80 /

+1.05 (+38.18%)

INM InMed Pharmaceuticals
$3.80 /

+1.05 (+38.18%)

05/16/22 Roth MKM
InMed Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
11/29/21 H.C. Wainwright
InMed Pharmaceuticals initiated with a Buy at H.C. Wainwright
INM InMed Pharmaceuticals
$3.80 /

+1.05 (+38.18%)

INM InMed Pharmaceuticals
$3.80 /

+1.05 (+38.18%)

Hot Stocks
InMed Pharmaceuticals announces launch of neurodegenerative disease program » 07:15
11/16/22
11/16
07:15
11/16/22
07:15
INM

InMed Pharmaceuticals

$2.75 /

-0.07 (-2.48%)

InMed Pharmaceuticals…

InMed Pharmaceuticals announces the launch of its neurodegenerative disease program, which will be investigating the effects of cannabinoid analogs in diseases such as Alzheimer's, Huntington's and Parkinson's. In research conducted to date, InMed has identified two cannabinoid analogs demonstrating promising effects related to the treatment of neurodegenerative diseases, warranting further investigation in in vivo studies. InMed will be conducting studies using in vivo models in neurodegenerative disease to select the most appropriate candidate for clinical studies. Early preclinical efficacy readout is expected in 2Q 2023. In addition, Dr. Ujendra Kumar of the faculty of Pharmaceuticals Sciences at UBC has been awarded an Alliance grant from NSERC, with InMed as the named industry partner. The funding will support the research and development studies of InMed's cannabinoid pharmaceutical candidates, investigating their potential therapeutic effects in neurodegenerative diseases. The collaboration project is entitled "Pharmacological characterization of phytocannabinoids and the endocannabinoid system."

ShowHide Related Items >><<
INM InMed Pharmaceuticals
$2.75 /

-0.07 (-2.48%)

INM InMed Pharmaceuticals
$2.75 /

-0.07 (-2.48%)

05/16/22 Roth MKM
InMed Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
11/29/21 H.C. Wainwright
InMed Pharmaceuticals initiated with a Buy at H.C. Wainwright
INM InMed Pharmaceuticals
$2.75 /

-0.07 (-2.48%)

INM InMed Pharmaceuticals
$2.75 /

-0.07 (-2.48%)

Earnings
InMed Pharmaceuticals reports Q1 EPS ($4.06) vs. ($6.17) a year ago » 18:57
11/11/22
11/11
18:57
11/11/22
18:57
INM

InMed Pharmaceuticals

$2.96 /

+0.14 (+4.96%)

The company realized…

The company realized sales of $0.3M in the BayMedica segment for the for the three months ended September 30, 2022, the result of the manufacturing and sale of bulk rare cannabinoid products following the acquisition of BayMedica in October 2021. As the period ended September 30, 2021 predated the acquisition of BayMedica, there are no comparable revenues in 2021.

ShowHide Related Items >><<
INM InMed Pharmaceuticals
$2.96 /

+0.14 (+4.96%)

INM InMed Pharmaceuticals
$2.96 /

+0.14 (+4.96%)

05/16/22 Roth MKM
InMed Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
11/29/21 H.C. Wainwright
InMed Pharmaceuticals initiated with a Buy at H.C. Wainwright
INM InMed Pharmaceuticals
$2.96 /

+0.14 (+4.96%)

INM InMed Pharmaceuticals
$2.96 /

+0.14 (+4.96%)

Over a quarter ago
Syndicate
InMed Pharmaceuticals files to sell 2.07M shares of common stock for holders  06:11
10/12/22
10/12
06:11
10/12/22
06:11
INM

InMed Pharmaceuticals

$6.14 /

-0.845 (-12.11%)

 
ShowHide Related Items >><<
INM InMed Pharmaceuticals
$6.14 /

-0.845 (-12.11%)

INM InMed Pharmaceuticals
$6.14 /

-0.845 (-12.11%)

05/16/22 Roth MKM
InMed Pharmaceuticals downgraded to Neutral from Buy at Roth Capital
11/29/21 H.C. Wainwright
InMed Pharmaceuticals initiated with a Buy at H.C. Wainwright
INM InMed Pharmaceuticals
$6.14 /

-0.845 (-12.11%)

INM InMed Pharmaceuticals
$6.14 /

-0.845 (-12.11%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.